Ibrexafungerp: A new triterpenoid antifungal.

Allana J SucherAnnie ThaiCharlene TranNetra MantenaAllwyn NoronhaElias B Chahine

Published in: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists (2022)

Ibrexafungerp is an alternative to fluconazole for the treatment of vulvovaginal candidiasis in nonpregnant females. It has the potential to be useful for recurrent and complicated vulvovaginal candidiasis as well as certain invasive fungal infections.

Keyphrases

candida albicans
human health